DGIdb - METFORMIN Drug Record

METFORMIN chembl:CHEMBL1431 ApprovedAntineoplastic

Alternate Names:

METFORMIN
LA-6023
N1,N1-DIMETHYLBIGUANIDE
OBIMET
DIANBEN
DIAFORMIN
METFORMINA
RIOMET
DIMETHYLBIGUANIDE
METFORMINUM
DIABEFAGOS
XLA399
GLUCOPHAGE
1,1-DIMETHYL BIGUANIDE
GLUMETZA
N,N-DIMETHYLBIGUANIDE
DIABEX
FORTAMET
1,1-DIMETHYLBIGUANIDE
GLUCOPHAGE®
METIGUANIDE
METFORMINE
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
DMBG
DIMETHYLBIGUANID
MEGUAN
pubchem.compound:4091
rxcui:6809
chemidplus:657-24-9
chembl:CHEMBL1431
drugbank:00331

Drug Info:

Year of Approval	1995
Drug Class	hypoglycemic agents
Drug Class	Small molecule
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antidiabetic
Drug Categories	drugs that are mainly renally excreted
Drug Categories	mate 1 substrates
Drug Categories	mate 2 substrates
Drug Categories	mate substrates
Drug Categories	oct1 substrates
Drug Categories	oct2 inhibitors

(6 More Sources)

Publications:

Tkáč I et al., 2015, A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes., Eur J Clin Pharmacol
Pedersen AJT et al., 2018, The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial., Basic Clin Pharmacol Toxicol
Santoro AB et al., 2018, Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort., Br J Clin Pharmacol
Goswami S et al., 2014, Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin., Clin Pharmacol Ther
Seo WD et al., 2015, Saponarin activates AMPK in a calcium-dependent manner and suppresses gluconeogenesis and increases glucose uptake via phosphorylation of CRTC2 and HDAC5., Bioorg Med Chem Lett
Gong L et al., 2012, Metformin pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
Vucicevic et al., 2009, AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C., Biochem. Pharmacol.
Ruderman et al., 2003, Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity., Endocrinology
Kovacic et al., 2003, Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart., J. Biol. Chem.
Towler et al., 2007, AMP-activated protein kinase in metabolic control and insulin signaling., Circ. Res.
Leverve et al., 2003, Mitochondrial metabolism and type-2 diabetes: a specific target of metformin., Diabetes Metab.
Musi et al., 2002, Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes., Diabetes
Hardie, 2003, Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status., Endocrinology
Leclerc et al., 2004, Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion., Am. J. Physiol. Endocrinol. Metab.
Sundelin E et al., 2017, Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans., Clin Pharmacol Ther
Dujic T et al., 2017, Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis., Clin Pharmacol Ther
Chien HC et al., 2016, Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells., Drug Metab Dispos
Todd JN et al., 2014, An update on the pharmacogenomics of metformin: progress, problems and potential., Pharmacogenomics
Tarasova L et al., 2012, Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients., Pharmacogenet Genomics
Becker ML et al., 2009, Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus., Pharmacogenomics J
Shu Y et al., 2008, Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics., Clin Pharmacol Ther
Shikata E et al., 2007, Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin., J Hum Genet
Christensen MM et al., 2011, The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c., Pharmacogenet Genomics
Dorosz J et al., 2010, Membrane interactions of novicidin, a novel antimicrobial peptide: phosphatidylglycerol promotes bilayer insertion., J Phys Chem B
Becker ML et al., 2010, Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response., Pharmacogenet Genomics
Tzvetkov MV et al., 2009, The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin., Clin Pharmacol Ther
Liu et al., 2016, High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum., Mol. Cancer Ther.
Iglesias et al., 2013, Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy., Mol. Cancer Ther.
Molenaar et al., 2015, Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198., Cancer Res.
Zakikhani et al., 2006, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells., Cancer Res.
Dowling et al., 2007, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells., Cancer Res.
Christensen MMH et al., 2015, Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers., Eur J Clin Pharmacol
Yoon H et al., 2013, Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects., AAPS J
He R et al., 2015, SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients., Diabetes Res Clin Pract
Christensen MM et al., 2013, A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin., Pharmacogenet Genomics
Stocker SL et al., 2013, The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin., Clin Pharmacol Ther
Tkáč I et al., 2013, Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes., Diabetes Obes Metab
Chung JY et al., 2013, Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics., Pharmacogenet Genomics
Choi JH et al., 2011, A common 5'-UTR variant in MATE2-K is associated with poor response to metformin., Clin Pharmacol Ther
Breitenstein MK et al., 2015, Leveraging an Electronic Health Record-Linked Biorepository to Generate a Metformin Pharmacogenomics Hypothesis., AMIA Jt Summits Transl Sci Proc
Liang X et al., 2015, Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3)., Mol Pharm
Vujic et al., 2015, Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer., Oncotarget
Rotroff DM et al., 2018, Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes., Diabetes
Chen EC et al., 2015, Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin., Mol Pharmacol
Chen L et al., 2010, Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin., Pharmacogenet Genomics
Ma et al., 2013, K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin., Mol Med Rep
Xie J et al., 2020, Metformin selectively inhibits metastatic colorectal cancer with the <i>KRAS</i> mutation by intracellular accumulation through silencing MATE1., Proc Natl Acad Sci U S A
Sesti G et al., 2006, The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes., J Clin Endocrinol Metab
Cufí et al., 2013, Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin., Oncotarget
Houlleberghs et al., 2016, Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants., Proc. Natl. Acad. Sci. U.S.A.
Sonnenblick et al., 2017, Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial., J. Clin. Oncol.
Viollet B et al., 2012, Cellular and molecular mechanisms of metformin: an overview., Clin Sci (Lond)
Fontaine E, 2018, Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences., Front Endocrinol (Lausanne)
Baur JA et al., 2014, Control of gluconeogenesis by metformin: does redox trump energy charge?, Cell Metab
Madiraju AK et al., 2014, Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase., Nature

METFORMIN SLC47A2

Interaction Score: 4.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28834135 25939711 24624919 23652408 23417334 23267855 22722338 21956618

Sources:
PharmGKB
METFORMIN PRKAB1

Interaction Score: 3.55

Interaction Types & Directionality:

inducer (activating)

activator (activating)

Interaction Info:

Trial Name glyburide + metformin,Glucovance

Novel drug target Established target

Trial Name metformin GR,Glumetza

PMIDs:
26471090 22722338 19428322 14500570 12890675 17307971 14502105 12086935 12960015 14871885

Sources:
DTC DrugBank TdgClinicalTrial TEND PharmGKB
METFORMIN SLC47A1

Interaction Score: 3.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28834135 26004431 24624919 23873119 23267855 22882994 22722338

Sources:
PharmGKB TTD
METFORMIN PRPF31

Interaction Score: 2.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29650774

Sources:
PharmGKB
METFORMIN NBEA

Interaction Score: 2.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29650774

Sources:
PharmGKB
METFORMIN PRKAB2

Interaction Score: 2.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26471090 22722338

Sources:
DTC PharmGKB
METFORMIN CPA6

Interaction Score: 2.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29650774

Sources:
PharmGKB
METFORMIN SLC19A3

Interaction Score: 2.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26528626

Sources:
PharmGKB
METFORMIN PRKAG3

Interaction Score: 2.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26471090 22722338

Sources:
DTC PharmGKB
METFORMIN FMO5

Interaction Score: 2.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26306225

Sources:
PharmGKB
METFORMIN PRKAG1

Interaction Score: 2.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26471090 22722338

Sources:
DTC PharmGKB
METFORMIN C11ORF65

Interaction Score: 2.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28834135

Sources:
PharmGKB
METFORMIN GPD1

Interaction Score: 2.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
25100057 24847880

Sources:
DrugBank
METFORMIN ETFDH

Interaction Score: 2.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
22117616 30619086

Sources:
DrugBank
METFORMIN SP1

Interaction Score: 2.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29352482 24853734

Sources:
PharmGKB
METFORMIN AMHR2

Interaction Score: 2.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29352482 24853734

Sources:
PharmGKB
METFORMIN PRKAG2

Interaction Score: 1.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26471090 22722338

Sources:
DTC PharmGKB
METFORMIN SLC22A1

Interaction Score: 1.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29352482 28834135 28380657 27859023 26700958 24624919 22735389 22722338 19381165 17609683 17111267 21989078 20690652 19898263 19536068

Sources:
PharmGKB
METFORMIN SLC22A3

Interaction Score: 1.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25920679 22722338 20859243

Sources:
PharmGKB
METFORMIN CAPN10

Interaction Score: 1.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25327507

Sources:
PharmGKB
METFORMIN SLC22A2

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25939711 24624919 23417334 22722338

Sources:
PharmGKB
METFORMIN PRKAA2

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22722338 26471090

Sources:
DTC PharmGKB
METFORMIN HNF1B

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
METFORMIN SLC2A2

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
METFORMIN SLC29A4

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22722338

Sources:
PharmGKB
METFORMIN ACACB

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
METFORMIN PRKAA1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26471090 22722338

Sources:
DTC PharmGKB
METFORMIN STK11

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type no benefit

Approval Status Preclinical

PMIDs:
17062558 18006825

Sources:
JAX-CKB
METFORMIN HRAS

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26921394 26951660

Sources:
JAX-CKB
METFORMIN KCNJ11

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16595597

Sources:
PharmGKB
METFORMIN NRAS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25504439

Sources:
CIViC
METFORMIN KRAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
23877793 24077915 32444490

Sources:
JAX-CKB CIViC
METFORMIN ATM

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28834135

Sources:
PharmGKB
METFORMIN PTEN

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

PMIDs:
26921394 24077915

Sources:
JAX-CKB
METFORMIN PPARA

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24853734

Sources:
PharmGKB
METFORMIN NR1I2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22722338

Sources:
PharmGKB
METFORMIN ERBB2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type predicted – sensitive

Approval Status Phase III

PMIDs:
28375706

Sources:
JAX-CKB
METFORMIN PIK3CA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
23986086

Sources:
JAX-CKB
METFORMIN MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
METFORMIN IDH1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26363012

Sources:
JAX-CKB

DrugBank: DB00331

Version: 5.1.7

Alternate Names:

METFORMIN DrugBank Drug Name

657-24-9 CAS Number

Acc-metformin Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories alimentary tract and metabolism

Publications:

Madiraju AK et al., 2014, Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase., Nature

Baur JA et al., 2014, Control of gluconeogenesis by metformin: does redox trump energy charge?, Cell Metab

Towler et al., 2007, AMP-activated protein kinase in metabolic control and insulin signaling., Circ. Res.

TEND: METFORMIN
- Version: 01-August-2011
Alternate Names:

METFORMIN Primary Drug Name

Drug Info:

Drug Class hypoglycemic agents

Year of Approval 1995

Publications:
TdgClinicalTrial: METFORMIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antidiabetic

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: METFORMIN

Version: 02-September-2020

Alternate Names:

CHEMBL1431 ChEMBL Drug ID

Drug Info:

Publications:

Seo WD et al., 2015, Saponarin activates AMPK in a calcium-dependent manner and suppresses gluconeogenesis and increases glucose uptake via phosphorylation of CRTC2 and HDAC5., Bioorg Med Chem Lett

PharmGKB: metformin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Tkáč I et al., 2015, A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes., Eur J Clin Pharmacol

Goswami S et al., 2014, Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin., Clin Pharmacol Ther

Santoro AB et al., 2018, Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort., Br J Clin Pharmacol

JAX-CKB: Metformin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Iglesias et al., 2013, Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy., Mol. Cancer Ther.

Ma et al., 2013, K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin., Mol Med Rep

Sonnenblick et al., 2017, Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial., J. Clin. Oncol.

CIViC: METFORMIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Vujic et al., 2015, Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer., Oncotarget

Xie J et al., 2020, Metformin selectively inhibits metastatic colorectal cancer with the <i>KRAS</i> mutation by intracellular accumulation through silencing MATE1., Proc Natl Acad Sci U S A

TTD: Metformin
- Version: 2020.06.01
Alternate Names:

D0D7LA TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1431
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: METFORMIN
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:

Trial Name	glyburide + metformin,Glucovance
Novel drug target	Established target
Trial Name	metformin GR,Glumetza

Indication/Tumor Type	Advanced Solid Tumor
Response Type	no benefit
Approval Status	Preclinical

Indication/Tumor Type	urinary bladder cancer
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	endometrial cancer
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	Her2-receptor positive breast cancer
Response Type	predicted – sensitive
Approval Status	Phase III

Indication/Tumor Type	colorectal cancer
Response Type	sensitive
Approval Status	Preclinical

METFORMIN	DrugBank Drug Name
657-24-9	CAS Number
Acc-metformin	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	alimentary tract and metabolism

inducer (activating)
activator (activating)

METFORMIN Drug Record

METFORMIN chembl:CHEMBL1431 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28834135 25939711 24624919 23652408 23417334 23267855 22722338 21956618

Sources: PharmGKB

Interaction Types & Directionality: inducer (activating) activator (activating)

Interaction Info: Trial Name glyburide + metformin,Glucovance Novel drug target Established target Trial Name metformin GR,Glumetza

PMIDs: 26471090 22722338 19428322 14500570 12890675 17307971 14502105 12086935 12960015 14871885

Sources: DTC DrugBank TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28834135 26004431 24624919 23873119 23267855 22882994 22722338

Sources: PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29650774

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29650774

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26471090 22722338

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29650774

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26528626

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26471090 22722338

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26306225

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26471090 22722338

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28834135

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 25100057 24847880

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 22117616 30619086

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29352482 24853734

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29352482 24853734

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26471090 22722338

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29352482 28834135 28380657 27859023 26700958 24624919 22735389 22722338 19381165 17609683 17111267 21989078 20690652 19898263 19536068

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25920679 22722338 20859243

Interaction Types & Directionality:

n/a

PMIDs:
28834135 25939711 24624919 23652408 23417334 23267855 22722338 21956618

Sources:
PharmGKB

Interaction Types & Directionality:

inducer (activating)

activator (activating)

Interaction Info:

Trial Name glyburide + metformin,Glucovance

Novel drug target Established target

Trial Name metformin GR,Glumetza

PMIDs:
26471090 22722338 19428322 14500570 12890675 17307971 14502105 12086935 12960015 14871885

Sources:
DTC DrugBank TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28834135 26004431 24624919 23873119 23267855 22882994 22722338

Sources:
PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
29650774

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29650774

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26471090 22722338

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29650774

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26528626

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26471090 22722338

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26306225

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26471090 22722338

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28834135

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
25100057 24847880

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
22117616 30619086

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
29352482 24853734

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29352482 24853734

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26471090 22722338

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29352482 28834135 28380657 27859023 26700958 24624919 22735389 22722338 19381165 17609683 17111267 21989078 20690652 19898263 19536068

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25920679 22722338 20859243

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25327507

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25939711 24624919 23417334 22722338

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22722338 26471090

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22722338

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a